{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:30:40Z","timestamp":1773660640631,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40259-015-0125-6","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T09:39:55Z","timestamp":1429609195000},"page":"143-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Olaparib: A Review of Its Use as Maintenance Therapy in Patients with Ovarian Cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,22]]},"reference":[{"key":"125_CR1","unstructured":"Cancer Research UK. Cancer mortality for common cancers. 2011. http:\/\/www.cancerresearchuk.org . Accessed 11 Dec 2014."},{"key":"125_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11\u201330.","journal-title":"CA Cancer J Clin."},{"issue":"Suppl 10","key":"125_CR3","doi-asserted-by":"crossref","first-page":"x118","DOI":"10.1093\/annonc\/mds315","volume":"23","author":"FA Raja","year":"2012","unstructured":"Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol. 2012;23(Suppl 10):x118\u201327.","journal-title":"Ann Oncol."},{"key":"125_CR4","unstructured":"European Medicines Agency. Lynparza. International non-proprietary name: Olaparib. European public assessment report. 2014. http:\/\/www.ema.europa.eu . Accessed 4 Mar 2015."},{"key":"125_CR5","doi-asserted-by":"crossref","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24\u201332.","DOI":"10.1093\/annonc\/mdt333"},{"key":"125_CR6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature."},{"key":"125_CR7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fonc.2014.00034","volume":"4","author":"WR Wiedemeyer","year":"2014","unstructured":"Wiedemeyer WR, Beach JA, Karlan BY. Reversing platinum resistance in high-grade serous ovarian carcinoma: targeting BRCA and the homologous recombination system. Front Oncol. 2014;4:34. doi: 10.3389\/fonc.2014.00034 .","journal-title":"Front Oncol."},{"issue":"8","key":"125_CR8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852\u201361.","journal-title":"Lancet Oncol."},{"issue":"5","key":"125_CR9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/CCO.0000000000000110","volume":"26","author":"S Khalique","year":"2014","unstructured":"Khalique S, Hook JM, Ledermann JA. Maintenance therapy in ovarian cancer. Curr Opin Oncol. 2014;26(5):521\u20138.","journal-title":"Curr Opin Oncol."},{"issue":"2","key":"125_CR10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1758834012467661","volume":"5","author":"A Garcia","year":"2013","unstructured":"Garcia A, Singh H. Bevacizumab and ovarian cancer. Ther Adv Med Oncol. 2013;5(2):133\u201341.","journal-title":"Ther Adv Med Oncol."},{"issue":"2","key":"125_CR11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00404-013-2856-2","volume":"288","author":"Y Chen","year":"2013","unstructured":"Chen Y, Zhang L, Hao Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet. 2013;288(2):367\u201374.","journal-title":"Arch Gynecol Obstet."},{"key":"125_CR12","first-page":"1197","volume":"6","author":"HM Shaw","year":"2013","unstructured":"Shaw HM, Hall M. Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Onco Targets Ther. 2013;6:1197\u2013206.","journal-title":"Onco Targets Ther."},{"issue":"5","key":"125_CR13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/21678707.2014.899147","volume":"2","author":"S Lheureux","year":"2014","unstructured":"Lheureux S, Oza AM. Olaparib for the treatment of ovarian cancer. Expert Opin Orphan Drugs. 2014;2(5):497\u2013508.","journal-title":"Expert Opin Orphan Drugs."},{"issue":"12","key":"125_CR14","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2165\/11635510-000000000-00000","volume":"72","author":"B Basu","year":"2012","unstructured":"Basu B, Sandhu SK, de Bono JS. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs. 2012;72(12):1579\u201390.","journal-title":"Drugs."},{"key":"125_CR15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fonc.2013.00228","volume":"3","author":"SB Lorenzo De","year":"2013","unstructured":"De Lorenzo SB, Patel AG, Hurley RM, et al. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol. 2013;3:228. doi: 10.3389\/fonc.2013.00228 .","journal-title":"Front Oncol."},{"issue":"1","key":"125_CR16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/annonc\/mdt384","volume":"25","author":"JM Lee","year":"2014","unstructured":"Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25(1):32\u201340.","journal-title":"Ann Oncol."},{"issue":"22","key":"125_CR17","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","volume":"26","author":"A Ashworth","year":"2008","unstructured":"Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785\u201390.","journal-title":"J Clin Oncol."},{"key":"125_CR18","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nm.3369","volume":"19","author":"CJ Lord","year":"2013","unstructured":"Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013;19:1381\u20138.","journal-title":"Nat Med."},{"key":"125_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2407-8-17","volume":"8","author":"JZ Press","year":"2008","unstructured":"Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008;8:17. doi: 10.1186\/1471-2407-8-17 .","journal-title":"BMC Cancer."},{"key":"125_CR20","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654\u201363.","journal-title":"J Clin Oncol."},{"key":"125_CR21","unstructured":"AstraZeneca AB. Lynparza 50\u00a0mg hard capsules: EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 11 Mar 2015."},{"key":"125_CR22","doi-asserted-by":"crossref","unstructured":"Sessa C. Update on PARP1 inhibitors in ovarian cancer. Ann Oncol. 2011;22(Suppl 8):viii72\u20136.","DOI":"10.1093\/annonc\/mdr528"},{"issue":"2","key":"125_CR23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123\u201334.","journal-title":"N Engl J Med."},{"issue":"4","key":"125_CR24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/1078-0432.CCR-10-1382","volume":"17","author":"U Kortmann","year":"2011","unstructured":"Kortmann U, McAlpine JN, Xue H, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res. 2011;17(4):783\u201391.","journal-title":"Clin Cancer Res."},{"issue":"9","key":"125_CR25","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.18632\/oncotarget.1929","volume":"5","author":"YE Choi","year":"2014","unstructured":"Choi YE, Battelli C, Watson J, et al. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget. 2014;5(9):2678\u201387.","journal-title":"Oncotarget."},{"issue":"3","key":"125_CR26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ygyno.2014.03.007","volume":"133","author":"PA Konstantinopoulos","year":"2014","unstructured":"Konstantinopoulos PA, Wilson AJ, Saskowski J, et al. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol Oncol. 2014;133(3):599\u2013606.","journal-title":"Gynecol Oncol."},{"issue":"3","key":"125_CR27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2014","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol. 2014;33(3):244\u201350.","journal-title":"J Clin Oncol."},{"issue":"9737","key":"125_CR28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245\u201351.","journal-title":"Lancet."},{"issue":"4","key":"125_CR29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","volume":"30","author":"SB Kaye","year":"2012","unstructured":"Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372\u20139.","journal-title":"J Clin Oncol."},{"issue":"9","key":"125_CR30","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852\u201361.","journal-title":"Lancet Oncol."},{"issue":"15","key":"125_CR31","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382\u201392.","journal-title":"N Engl J Med."},{"key":"125_CR32","unstructured":"AstraZeneca Pharmaceuticals LP. Lynparza\u2122 (olaparib) capsules, for oral use: US prescribing information. 2014. http:\/\/www.accessdata.fda.gov . Accessed 11 Mar 2015."},{"key":"125_CR33","doi-asserted-by":"crossref","unstructured":"Molife LR, Forster MD, Krebs M, et al. A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors (abstract no. 2599). J Clin Oncol. 2010;28(15 Suppl).","DOI":"10.1200\/jco.2010.28.15_suppl.2599"},{"key":"125_CR34","doi-asserted-by":"crossref","unstructured":"Molife LR, Mateo J, McGoldrick T, et al. Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1\/2 mutations (abstract no. 3048). J Clin Oncol. 2012;30(Suppl).","DOI":"10.1200\/jco.2012.30.15_suppl.3048"},{"key":"125_CR35","first-page":"S161","volume":"49","author":"J Mateo","year":"2013","unstructured":"Mateo J, Friedlander M, Sessa C, et al. Administration of continuous\/intermittent olaparib in ovarian cancer patients with a germline BRCA1\/2 mutation to determine an optimal dosing schedule for the tablet formulation (abstract no. 801). Eur J Cancer. 2013;49:S161.","journal-title":"Eur J Cancer."},{"key":"125_CR36","doi-asserted-by":"crossref","unstructured":"Moore KN, Di Silvestro P, Lowe ES, et al. SOLO1 and SOLO2: randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1\/2 mutation (BRCAm) (abstract no. TPS5616). J Clin Oncol. 2014;32(5 Suppl).","DOI":"10.1200\/jco.2014.32.15_suppl.tps5616"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-015-0125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-015-0125-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-015-0125-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T04:04:17Z","timestamp":1598933057000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-015-0125-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["125"],"URL":"https:\/\/doi.org\/10.1007\/s40259-015-0125-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}